Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.54 |
| ▸ | CES1 | P23141 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15898020 | 1.00 | CES2 (0.54) | CES2CES1ALDH1A1TDP1MAPK1 | |
| SCHEMBL11467759 | 0.87 | LTA4H (0.56) | L3MBTL1SLC6A2SLC6A3LMNA | |
| SCHEMBL8792903 | 0.85 | PTGS1 (0.51) | ALDH1A1SLC6A2LMNATSHR | |
| SCHEMBL3206832 | 0.84 | ALDH1A1 (0.61) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL6772418 | 0.83 | RAB9A (0.53) | ALDH1A1TDP1 | |
| SCHEMBL10596245 | 0.83 | ALDH1A1 (0.55) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL27722038 | 0.82 | ALDH1A1 (0.59) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL535789 | 0.82 | CES2 (0.51) | CES2CES1ALDH1A1TDP1MAPK1 | |
| SCHEMBL535788 | 0.82 | CES2 (0.51) | CES2CES1ALDH1A1TDP1MAPK1 | |
| SCHEMBL11526737 | 0.81 | ALDH1A1 (0.57) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2931729-B1 | BUPRENORPHINE ANALOGS AS OPIOD RECEPTOR MODULATORS | PURDUE PHARMA LP (US) | 2019-02-06 | — | — | EP | disclosed |
| US-20170240660-A1 | USING ORGANIC PHOTOREDOX CATALYSTS TO ACHIEVE METAL FREE PHOTOREGULATED CONTROLLED RADICAL POLYMERIZATION | DOW GLOBAL TECHNOLOGIES LLC | 2017-08-24 | — | — | US | disclosed |
| US-9175000-B2 | Buprenorphine analogs | PURDUE PHARMA L.P. (US) | 2015-11-03 | — | — | US | disclosed |
| EP-2931729-A1 | BUPRENORPHINE ANALOGS AS OPIOD RECEPTOR MODULATORS | Purdue Pharma LP (US) | 2015-10-21 | — | — | EP | disclosed |
| WO-2014087226-A1 | BUPRENORPHINE ANALOGS AS OPIOD RECEPTOR MODULATORS | PURDUE PHARMA L.P. (US) | 2014-06-12 | — | — | WO | disclosed |
| US-20140163058-A1 | BUPRENORPHINE ANALOGS | PURDUE PHARMA L.P. (US) | 2014-06-12 | — | — | US | disclosed |
| CN-101687758-B | Substituted biphenyl carboxylic acids and derivatives thereof | ORTHO MCNEIL PHARM INC | 2014-05-14 | — | — | CN | disclosed |
| CN-101687758-A | Substituted biphenyl carboxylic acids and derivatives thereof | ORTHO MCNEIL PHARM INC | 2010-03-31 | — | — | CN | disclosed |
| US-4764518-A | Antibacterial agents containing oxo-4-pyridine carboxylic acid derivatives | PANMEDICA (FR) | 1988-08-16 | — | — | US | disclosed |
| US-4559342-A | Quinolone acids and antibacterial agents containing these compounds | BAYER AKTIENGESELLSCHAFT (DE) | 1985-12-17 | — | — | US | disclosed |
| US-4472300-A | ANTIMICROBIAL | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-09-18 | — | — | US | disclosed |
| US-4207234-A | 4-Unsubstituted azetidinone derivatives and process for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163058-A1 | BUPRENORPHINE ANALOGS | OPRL1, OPRK1, OPRD1 | CES2 1329/4885CES1 2018/4885ALDH1A1 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.